PURPOSE: The objectives of this phase I trial were to determine the maximum-tolerated dose (MTD), toxicity profile, dose-limiting toxicities (DLTs), pharmacokinetics, and preliminary response rate for ixabepilone, a microtubule-stabilizing agent, administered intravenously daily for 5 days in children and adolescents. PATIENTS AND METHODS: Patients >or= 2 and <or= 18 years with relapsed or refractory solid tumors were enrolled onto sequential cohorts to the following five dose levels: 3.0 (n = 3), 4.5 (n = 4), 6.0 (n = 3), 8.0 (n = 6), and 10 (n = 3) mg/m(2)/d. Eligibility criteria, dose levels, definitions of DLT and MTD, and pharmacokinetic sampling times were designed to be as similar as possible to the adult phase I trial of ixabepilone on the same schedule. RESULTS: Nineteen children (median age, 10 years; range, 2 to 18 years) were enrolled, and 18 (12 with sarcomas) were assessable for toxicity. DLTs (grade 4 neutropenia for > 5 days and grade 3 fatigue) were observed in two of three patients receiving 10 mg/m(2)/d. The MTD of ixabepilone administered daily for 5 days every 21 days was 8 mg/m(2)/d. Myelosuppression, GI, and hepatic toxicities were common non-DLTs. Peripheral neuropathy was uncommon. Ixabepilone clearance was 475 +/- 247 mL/min/m(2), volume of distribution at steady-state was 12.2 +/- 5.4 L/kg, and half-life was 14 hours. CONCLUSION: The recommended dose of ixabepilone for phase II trials in solid tumors is 8 mg/m(2)/d daily for 5 days every 21 days. This dose is 33% higher than the MTD in adults receiving the same dosing schedule. Pharmacokinetic parameters in children and adolescents were highly variable but similar to adults.
PURPOSE: The objectives of this phase I trial were to determine the maximum-tolerated dose (MTD), toxicity profile, dose-limiting toxicities (DLTs), pharmacokinetics, and preliminary response rate for ixabepilone, a microtubule-stabilizing agent, administered intravenously daily for 5 days in children and adolescents. PATIENTS AND METHODS: Patients >or= 2 and <or= 18 years with relapsed or refractory solid tumors were enrolled onto sequential cohorts to the following five dose levels: 3.0 (n = 3), 4.5 (n = 4), 6.0 (n = 3), 8.0 (n = 6), and 10 (n = 3) mg/m(2)/d. Eligibility criteria, dose levels, definitions of DLT and MTD, and pharmacokinetic sampling times were designed to be as similar as possible to the adult phase I trial of ixabepilone on the same schedule. RESULTS: Nineteen children (median age, 10 years; range, 2 to 18 years) were enrolled, and 18 (12 with sarcomas) were assessable for toxicity. DLTs (grade 4 neutropenia for > 5 days and grade 3 fatigue) were observed in two of three patients receiving 10 mg/m(2)/d. The MTD of ixabepilone administered daily for 5 days every 21 days was 8 mg/m(2)/d. Myelosuppression, GI, and hepatic toxicities were common non-DLTs. Peripheral neuropathy was uncommon. Ixabepilone clearance was 475 +/- 247 mL/min/m(2), volume of distribution at steady-state was 12.2 +/- 5.4 L/kg, and half-life was 14 hours. CONCLUSION: The recommended dose of ixabepilone for phase II trials in solid tumors is 8 mg/m(2)/d daily for 5 days every 21 days. This dose is 33% higher than the MTD in adults receiving the same dosing schedule. Pharmacokinetic parameters in children and adolescents were highly variable but similar to adults.
Authors: Jennifer K Peterson; Chandra Tucker; Edward Favours; Pamela J Cheshire; Jeremy Creech; Catherine A Billups; Richard Smykla; Francis Y F Lee; Peter J Houghton Journal: Clin Cancer Res Date: 2005-10-01 Impact factor: 12.531
Authors: N L Seibel; S M Blaney; M O'Brien; M Krailo; R Hutchinson; R B Mosher; F M Balis; G H Reaman Journal: Clin Cancer Res Date: 1999-04 Impact factor: 12.531
Authors: Sen H Zhuang; Manish Agrawal; Maureen Edgerly; Susan Bakke; Herb Kotz; Paul Thambi; Ann Rutt; Frank M Balis; Susan Bates; Tito Fojo Journal: Cancer Date: 2005-05-01 Impact factor: 6.860
Authors: Matthew D Galsky; Eric J Small; William K Oh; Isan Chen; David C Smith; A Dimitrios Colevas; Lou Martone; Tracy Curley; Anthony Delacruz; Howard I Scher; W Kevin Kelly Journal: J Clin Oncol Date: 2005-03-01 Impact factor: 44.544
Authors: Carol Aghajanian; Howard A Burris; Suzanne Jones; David R Spriggs; Marvin B Cohen; Ronald Peck; Paul Sabbatini; Martee L Hensley; F Anthony Greco; Jakob Dupont; Owen A O'Connor Journal: J Clin Oncol Date: 2007-01-29 Impact factor: 44.544
Authors: Maha Hussain; Catherine M Tangen; Primo N Lara; Ulka N Vaishampayan; Daniel P Petrylak; A Dimitrios Colevas; Wael A Sakr; E David Crawford Journal: J Clin Oncol Date: 2005-12-01 Impact factor: 44.544
Authors: J A Ajani; H Safran; C Bokemeyer; M A Shah; H-J Lenz; E Van Cutsem; H A Burris; D Lebwohl; B Mullaney Journal: Invest New Drugs Date: 2006-09 Impact factor: 3.850
Authors: Neelima Denduluri; Jennifer A Low; James J Lee; Arlene W Berman; Janice M Walshe; Ujala Vatas; Catherine K Chow; Seth M Steinberg; Sherry X Yang; Sandra M Swain Journal: J Clin Oncol Date: 2007-07-02 Impact factor: 44.544
Authors: Elizabeth Fox; John M Maris; Brigitte C Widemann; Kysa Meek; Anne Goodwin; Wendy Goodspeed; Marie Kromplewski; Molly E Fouts; Diane Medina; Steve Y Cho; Susan L Cohn; Andrew Krivoshik; Anne E Hagey; Peter C Adamson; Frank M Balis Journal: Clin Cancer Res Date: 2006-08-15 Impact factor: 13.801
Authors: Shana Jacobs; Elizabeth Fox; Mark Krailo; Gwen Hartley; Fariba Navid; Leonard Wexler; Susan M Blaney; Anne Goodwin; Wendy Goodspeed; Frank M Balis; Peter C Adamson; Brigitte C Widemann Journal: Clin Cancer Res Date: 2010-01-12 Impact factor: 12.531
Authors: Ron J Keizer; Anthe S Zandvliet; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Invest New Drugs Date: 2011-05-28 Impact factor: 3.850